Mo’ money, fewer problems: The Tipline for 4 May 2017

Today we dive into the proposed federal spending bill to see how it might affect antitrust enforcement in the US. We also have coverage of six pharmaceutical companies’ ongoing battle against 40 states regarding two generic drugs, and a deeper look into Tim Muris’ jump to Sidley Austin.

Get unlimited access to all Global Competition Review content